# Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

> **NCT03568162** · PHASE2 · COMPLETED · sponsor: **Ichnos Sciences SA** · enrollment: 462 (actual)

## Conditions studied

- Moderate to Severe Atopic Dermatitis

## Interventions

- **DRUG:** ISB 830 - Part 1 Group 1
- **DRUG:** ISB 830 - Part 1 Group 2
- **DRUG:** ISB 830 - Part 1 Group 3
- **DRUG:** Placebo - Part 1 Group 4
- **DRUG:** ISB 830 - Part 2 Group 5
- **DRUG:** Placebo - Part 2 Group 6

## Key facts

- **NCT ID:** NCT03568162
- **Lead sponsor:** Ichnos Sciences SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-31
- **Primary completion:** 2020-08-11
- **Final completion:** 2021-08-03
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2022-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568162, "Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03568162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*